SYDNEY, Australia, 28 February 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Professor Ursula Wiedermann will present on the HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting.
The poster (abstract number 8249) will be presented by Prof Wiedermann, the co-inventor of the HER-Vaxx cancer vaccine and member of the Company’s Scientific Advisory Board, at the AACR Annual Meeting in Atlanta, Georgia scheduled for March 29 to April 3, 2019.
The abstract presentation is entitled ‘A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced cancer of the stomach.’
For further information please download PDF attached:
Download this document
